Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices: Results from TARGET

Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy

BACKGROUND AND STUDY AIMS Discontinuation of all antiplatelet agents before endoscopic procedures may cause serious complications in some patients. The aim of this study was to evaluate the hemorrhagic risk of post-endoscopic submucosal dissection (ESD) in patients on antiplatelet therapy (APT). PATIENTS AND METHODS The subjects were 350 patients (377 lesions) who underwent gastric ESD betwee...

Femoral access management: comparison between two different vascular closure devices after percutaneous coronary intervention.

OBJECTIVES Several devices have been proposed as an alternative to manual compression (MC) for femoral access management (FAME) following catheterization. Although these devices allow earlier ambulation, they have not always been shown to reduce vascular complications. As a consequence, their cost efficacy is not obvious. METHODS During MC a special catheter deployed temporarily within the ar...

Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

BACKGROUND The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that bivalirudin monotherapy significantly reduces major bleeding compared with heparin (unfractionated or enoxaparin) or bivalirudin plus a glycoprotein IIb/IIIa inhibitor in acute coronary syndromes. Whether vascular closure devices (VCD) impact these results is unknown. Therefore, this st...

Does Tranexamic Acid Reduce Bleeding during Femoral Fracture Operation?

Background:Proximal Femoral shaft fractures are commonly associated with marked blood loss which can lead topostoperative acute anemia and some other complications.Tranexamic acid (TA) is an antifibrinolytic medication that reduces intra-and postoperative blood loss and transfusionrequirements during some elective surgeries (1-3).The aim of this study is to evaluate the effect of intravenous Tr...

Genetic testing in antiplatelet therapy – not effective for perioperative bleeding